LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Inicio・Lista de Acciones・Editas Medicine Inc

Editas Medicine Inc

Cerrado

SectorSalud

1.5 7.91

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.33

Máximo

1.5

Métricas clave
By Trading Economics
Ingresos	-31M -76M
Ventas	-26M 4.7M
BPA	-0.55
Margen de beneficio	-1,633.491
Empleados	246
EBITDA	28M -33M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+125.36% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-17M 129M
Apertura anterior	-6.41
Cierre anterior	1.5

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

124 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.33 / 1.54 Soporte y Resistencia

Editas Medicine Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2025, 22:52 UTC

Ganancias

Principales Movimientos del Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 may 2025, 20:37 UTC

Principales Noticias

Ganancias

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 may 2025, 00:00 UTC

Charlas de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 may 2025, 23:47 UTC

Charlas de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 may 2025, 23:14 UTC

Principales Noticias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 may 2025, 22:46 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 21:58 UTC

Ganancias

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 may 2025, 21:24 UTC

Ganancias

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 may 2025, 20:56 UTC

Charlas de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 may 2025, 20:54 UTC

Charlas de Mercado

Ganancias

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 may 2025, 20:54 UTC

Ganancias

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 may 2025, 20:51 UTC

Ganancias

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 may 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 may 2025, 20:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 may 2025, 20:50 UTC

Ganancias

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 may 2025, 20:26 UTC

Principales Noticias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 may 2025, 20:25 UTC

Ganancias

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparación entre iguales

Cambio de precio

Editas Medicine Inc Esperado

Precio Objetivo

By TipRanks

125.36% repunte

Estimación a 12 meses

Media 3.11 USD 125.36%

Máximo 5 USD

Mínimo 1 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Editas Medicine Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Editas Medicine Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.33 / 1.54Soporte y Resistencia

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentimiento

By Acuity

124 / 382 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.